Abstract Immunotherapies are effective in a subset of patients with non-small cell lung cancer (NSCLC), however the majority do not respond which highlights the ongoing need for novel therapeutics and biomarkers. Tumor cells can produce cytokines and chemokines that influence both the recruitment and function of immune cells. In patients with NSCLC, the microRNA-17~92 (miR-17~92) cluster was shown to be upregulated, and high levels of microRNA-17 in serum was associated with decreased survival. We aimed to identify whether tumor cell intrinsic mechanisms, like upregulation of miR-17~92, regulate chemokine or cytokine production to induce an immunosuppressive tumor microenvironment and inhibit CD8+ T cell anti-tumor function in the lung. We used the CIBERSORTX program to evaluate alterations to immune cell populations and survival in NSCLC patients with increased chemokine or miR-17~92 expression. We found high expression of miR-17 and low expression of IL-7Rα correlated with decreased survival in lung adenocarcinoma (LAC) patients. Furthermore, LAC patient’s tumor biopsies with high miR-17 had decreased IL-7Rα and increased populations of CD8+ T cells by CIBERSORTX. We will use in vitro and in vivo models of lung cancer to determine whether miR-17~92 upregulation and tumor cell chemokines and cytokines production drives immunosuppression in the tumor microenvironment. Understanding how lung tumor cells regulate cytokines and chemokines, and their putative control of exhaustion in CD8 T cells in the tumor microenvironment would guide selection of efficacious immunotherapy treatment.